Trials / Completed
CompletedNCT04667052
A Study to Compare Two Different Subcutaneously-administered JNJ-64304500 Formulations in Healthy Participants
An Open-label, Randomized, Parallel Group Study to Assess the Relative Bioavailability of Two Different Subcutaneously-Administered JNJ-64304500 Formulations in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the relative bioavailability of JNJ-64304500 after administration of two different formulations in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ 64304500 | Participants will receive a single subcutaneous dose of JNJ-64304500 reference formulation. |
| DRUG | JNJ 64304500 | Participants will receive a single subcutaneous dose of JNJ-64304500 test formulation. |
Timeline
- Start date
- 2021-01-13
- Primary completion
- 2021-06-15
- Completion
- 2021-06-15
- First posted
- 2020-12-14
- Last updated
- 2025-02-03
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04667052. Inclusion in this directory is not an endorsement.